ERBB2 and adenocarcinoma: These indications include nivolumab plus chemotherapy in the first-line treatment of HER2-negative adenocarcinoma with CPS ≥ 5 and squamous cell carcinoma with ≥ 1% PD-L1 expression, nivolumab plus ipilimumab in the first-line treatment of squamous cell carcinoma with ≥ 1% PD-L1 expression, and nivolumab monotherapy in the second-line treatment of squamous cell carcinoma.